Medistep Healthcare Ltd
Incorporated in June 2023, Medistep Healthcare Ltd manufactures and trades healthcare and personal care products.[1]
- Market Cap ₹ 29.1 Cr.
- Current Price ₹ 20.5
- High / Low ₹ 30.0 / 16.5
- Stock P/E 4.87
- Book Value ₹ 26.6
- Dividend Yield 0.00 %
- ROCE 27.0 %
- ROE 21.7 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.77 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 203 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Personal Products Personal Care
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 9m | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 31.60 | 49.65 | 70.83 | |
| 27.64 | 44.04 | 62.57 | |
| Operating Profit | 3.96 | 5.61 | 8.26 |
| OPM % | 12.53% | 11.30% | 11.66% |
| 0.01 | 0.00 | 0.02 | |
| Interest | 0.06 | 0.04 | 0.26 |
| Depreciation | 0.02 | 0.03 | 0.03 |
| Profit before tax | 3.89 | 5.54 | 7.99 |
| Tax % | 25.19% | 25.09% | 25.16% |
| 2.91 | 4.14 | 5.98 | |
| EPS in Rs | 5.94 | 3.96 | 4.21 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 24% |
| Last Year: | 22% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 4.90 | 10.47 | 14.21 |
| Reserves | 6.79 | 6.89 | 23.62 |
| 0.33 | 0.64 | 5.18 | |
| 2.93 | 5.00 | 7.29 | |
| Total Liabilities | 14.95 | 23.00 | 50.30 |
| 0.15 | 0.14 | 0.12 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| 14.80 | 22.86 | 50.18 | |
| Total Assets | 14.95 | 23.00 | 50.30 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -7.11 | 0.02 | -19.48 | |
| -0.15 | 0.00 | -0.01 | |
| 7.24 | 1.28 | 18.79 | |
| Net Cash Flow | -0.02 | 1.30 | -0.70 |
| Free Cash Flow | -7.26 | 0.02 | -19.49 |
| CFO/OP | -180% | 0% | -224% |
Ratios
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 158.82 | 147.84 | 202.98 |
| Inventory Days | 12.41 | 9.23 | 36.52 |
| Days Payable | 18.81 | 20.55 | 21.57 |
| Cash Conversion Cycle | 152.42 | 136.52 | 217.93 |
| Working Capital Days | 133.76 | 116.89 | 191.18 |
| ROCE % | 37.18% | 27.04% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Manufacturing Revenue Share % |
|
|||
| Number of Employees count |
||||
| Top 10 Customer Concentration % |
||||
| Number of Distributors/Stockists count |
||||
Extracted by Screener AI
Documents
Announcements
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
- Medistep says corporate governance report not applicable for quarter and half year ended 30 September 2026.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter and half year ended 30 September 2026.
-
Trading Window
- Trading window closed from 1 Oct 2026 until 48 hours after half-year results.
-
Shareholders meeting
- Medistep Healthcare’s 3rd AGM on Sept. 17, 2026 approved 3 resolutions, including FY26 audited accounts and loan threshold increase.
-
Shareholders meeting
- Medistep Healthcare held its 3rd AGM on September 17, 2026; adopted accounts, reappointed director, approved Section 186 limits.
Business Overview:[1]
MHL is engaged in the business of manufacturing of sanitary pads and energy powder, as well as the
trading and distribution of a wide range of healthcare products comprising pharmaceutical
formulations, nutraceutical products, intimate care products, and surgical supplies.